Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • بيانات النشر:
      Elsevier
    • الموضوع:
      2023
    • Collection:
      Universidade de Lisboa: repositório.UL
    • نبذة مختصرة :
      © 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). ; Background & aims: The response of patients with chronic liver disease (CLD) to COVID-19 vaccines remains unclear. Our aim was to assess the humoral immune response and efficacy of two-dose COVID-19 vaccines among patients with CLD of different aetiologies and disease stages. Methods: A total of 357 patients were recruited in clinical centres from six European countries, and 132 healthy volunteers served as controls. Serum IgG (nM), IgM (nM), and neutralising antibodies (%) against the Wuhan-Hu-1, B.1.617, and B.1.1.529 SARS-CoV-2 spike proteins were determined before vaccination (T0) and 14 days (T2) and 6 months (T3) after the second-dose vaccination. Patients fulfilling inclusion criteria at T2 (n = 212) were stratified into 'low' or 'high' responders according to IgG levels. Infection rates and severity were collected throughout the study. Results: Wuhan-Hu-1 IgG, IgM, and neutralisation levels significantly increased from T0 to T2 in patients vaccinated with BNT162b2 (70.3%), mRNA-1273 (18.9%), or ChAdOx1 (10.8%). In multivariate analysis, age, cirrhosis, and type of vaccine (ChAdOx1 > BNT162b2 > mRNA-1273) predicted 'low' humoral response, whereas viral hepatitis and antiviral therapy predicted 'high' humoral response. Compared with Wuhan-Hu-1, B.1.617 and, further, B.1.1.529 IgG levels were significantly lower at both T2 and T3. Compared with healthy individuals, patients with CLD presented with lower B.1.1.529 IgGs at T2 with no additional key differences. No major clinical or immune IgG parameters associated with SARS-CoV-2 infection rates or vaccine efficacy. Conclusions: Patients with CLD and cirrhosis exhibit lower immune responses to COVID-19 vaccination, irrespective of disease aetiology. The type of vaccine leads to different antibody responses that appear not ...
    • ISSN:
      2589-5559
    • Relation:
      info:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FMED-PAT%2F31882%2F2017/PT; info:eu-repo/grantAgreement/FCT/3599-PPCDT/EXPL%2FMED-OUT%2F1317%2F2021/PT; https://www.sciencedirect.com/journal/jhep-reports; JHEP Rep. 2023 May;5(5):100697; http://hdl.handle.net/10451/57127
    • الرقم المعرف:
      10.1016/j.jhepr.2023.100697
    • الدخول الالكتروني :
      http://hdl.handle.net/10451/57127
      https://doi.org/10.1016/j.jhepr.2023.100697
    • Rights:
      openAccess ; http://creativecommons.org/licenses/by-nc-nd/4.0/
    • الرقم المعرف:
      edsbas.186AE3F